Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
Tel: +86-29-86719484
Tel: +86 15529365669
Tel: +86-29-86719484
Tel: +8615529365669
Mobile: +86 17782579994
Tel: +86-29-86719484
Fax: +86-29-86719484
Province/state: Shaanxi
City: Xi'an
Street: B-1604,Juncheng Guoji, Taiyuan Road, Weiyang distirct
MaxCard:
CAS NO.42971-09-5
99%(100-500)Kilogram99%(500-1000)Kilogram
exporter Vincamine powder Reliable quality Vincamine 42971-09-5 on hot selling
Vinpocetine is a semisynthetic alkaloid commonly used as an inhibitor of phosphodiesterase 1 (PDE1), blocking the hydrolysis of both cAMP and cGMP (Ki = 14 µM). In addition to its use as a selective PDE1 inhibitor in basic research, vinpocetine has diverse cerebral and neurological effects in vivo. Vinpocetine also directly inhibits the kinase activity of IKKβ (IC50 = 17 µM in a cell-free system) and blocks TNF-α- and LPS-mediated activation of NF-κB in cells and in vivo.
Vinpocetine is also called Ethyl apovincaminate, Conway, Karan and Vinpocetine. It is a kind of natural medicine extracted from small vinca flower, and belongs to the indole alkaloids. Can be synthetic now. The mechanism of its pharmacological action is to inhibit the activity of calcium dependency phosphodiesterase, increase the content of CGMP which can relax vascular smooth muscle, then relax vascular smooth muscle, and further increase cerebral blood flow; Enhance the capacity of deformation of red blood cells, reduce blood viscosity, inhibit platelet aggregation, and thus improve blood flow and microcirculation; Promote the brain tissue to absorb glucose, and promote the transformation of brain monoamine metabolism; Inhibit the increase of brain lactic acid during cerebral ischemia, increase the ATP content, increase thedegree of oxygen dissociation in hemoglobin; Increase the resistance capacity for cerebral anoxia and occurring of spasm caused by cerebral ischemia, inhibit the generation of lipid peroxide in the brain. Oral absorption effectively, reach peak at 1 h, then metabolize into Vinpocetine in the body. The half-life of plasma elimination is about 1 hour. For 4 weeks in a row, no accumulation in the body. Clinical used in cerebral infarction sequela, cerebral hemorrhage sequelae, cerebral arteriosclerosis, cerebral vasospasm, brain endarteritis caused vertigo, tinnitus, headache, dizziness, limb numbness, incontinence and other clinical manifestations, depression, anxiety, sleep disorder and other mental symptoms. Clinical experience has shown that it is effective regardless of the length of the course of the disease, and the symptom is fixed or not.
Vinpocetine
Ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate
C22H26N2O2
350.45
42971-09-5
256-028-0
98% min
HNMR/IR